These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Diencephalic serotonin transporter availability predicts both transporter occupancy and treatment response to sertraline in obsessive-compulsive checkers. Zitterl W; Stompe T; Aigner M; Zitterl-Eglseer K; Ritter K; Zettinig G; Hornik K; Asenbaum S; Pirker W; Thau K Biol Psychiatry; 2009 Dec; 66(12):1115-22. PubMed ID: 19717141 [TBL] [Abstract][Full Text] [Related]
3. Serotonin transporter gene promoter polymorphisms modify the association between paroxetine serotonin transporter occupancy and clinical response in major depressive disorder. Ruhé HG; Ooteman W; Booij J; Michel MC; Moeton M; Baas F; Schene AH Pharmacogenet Genomics; 2009 Jan; 19(1):67-76. PubMed ID: 18987562 [TBL] [Abstract][Full Text] [Related]
4. Occupancy of serotonin transporters in the amygdala by paroxetine in association with attenuation of left amygdala activation by negative faces in major depressive disorder. Ruhé HG; Koster M; Booij J; van Herk M; Veltman DJ; Schene AH Psychiatry Res; 2014 Feb; 221(2):155-61. PubMed ID: 24406081 [TBL] [Abstract][Full Text] [Related]
5. Displacement of serotonin and dopamine transporters by venlafaxine extended release capsule at steady state: a [123I]2beta-carbomethoxy-3beta-(4-iodophenyl)-tropane single photon emission computed tomography imaging study. Shang Y; Gibbs MA; Marek GJ; Stiger T; Burstein AH; Marek K; Seibyl JP; Rogers JF J Clin Psychopharmacol; 2007 Feb; 27(1):71-5. PubMed ID: 17224717 [TBL] [Abstract][Full Text] [Related]
6. Validation of [(123)I]beta-CIT SPECT to assess serotonin transporters in vivo in humans: a double-blind, placebo-controlled, crossover study with the selective serotonin reuptake inhibitor citalopram. de Win MM; Habraken JB; Reneman L; van den Brink W; den Heeten GJ; Booij J Neuropsychopharmacology; 2005 May; 30(5):996-1005. PubMed ID: 15770240 [TBL] [Abstract][Full Text] [Related]
7. Evidence why paroxetine dose escalation is not effective in major depressive disorder: a randomized controlled trial with assessment of serotonin transporter occupancy. Ruhé HG; Booij J; v Weert HC; Reitsma JB; Franssen EJ; Michel MC; Schene AH Neuropsychopharmacology; 2009 Mar; 34(4):999-1010. PubMed ID: 18830236 [TBL] [Abstract][Full Text] [Related]
8. Central serotonin transporter availability measured with [123I]beta-CIT SPECT in relation to serotonin transporter genotype. van Dyck CH; Malison RT; Staley JK; Jacobsen LK; Seibyl JP; Laruelle M; Baldwin RM; Innis RB; Gelernter J Am J Psychiatry; 2004 Mar; 161(3):525-31. PubMed ID: 14992979 [TBL] [Abstract][Full Text] [Related]
12. Occupancy of brain serotonin transporters during treatment with paroxetine in patients with social phobia: a positron emission tomography study with 11C McN 5652. Kent JM; Coplan JD; Lombardo I; Hwang DR; Huang Y; Mawlawi O; Van Heertum RL; Slifstein M; Abi-Dargham A; Gorman JM; Laruelle M Psychopharmacology (Berl); 2002 Dec; 164(4):341-8. PubMed ID: 12457263 [TBL] [Abstract][Full Text] [Related]
13. Changes in thalamus-hypothalamus serotonin transporter availability during clomipramine administration in patients with obsessive-compulsive disorder. Zitterl W; Aigner M; Stompe T; Zitterl-Eglseer K; Gutierrez-Lobos K; Wenzel T; Zettinig G; Hornik K; Pirker W; Thau K Neuropsychopharmacology; 2008 Dec; 33(13):3126-34. PubMed ID: 18354388 [TBL] [Abstract][Full Text] [Related]
14. Quantification of striatal dopamine transporters with 123I-FP-CIT SPECT is influenced by the selective serotonin reuptake inhibitor paroxetine: a double-blind, placebo-controlled, crossover study in healthy control subjects. Booij J; de Jong J; de Bruin K; Knol R; de Win MM; van Eck-Smit BL J Nucl Med; 2007 Mar; 48(3):359-66. PubMed ID: 17332612 [TBL] [Abstract][Full Text] [Related]
15. Reduced brain serotonin transporter availability in major depression as measured by [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane and single photon emission computed tomography. Malison RT; Price LH; Berman R; van Dyck CH; Pelton GH; Carpenter L; Sanacora G; Owens MJ; Nemeroff CB; Rajeevan N; Baldwin RM; Seibyl JP; Innis RB; Charney DS Biol Psychiatry; 1998 Dec; 44(11):1090-8. PubMed ID: 9836013 [TBL] [Abstract][Full Text] [Related]
16. Serotonin transporter occupancy induced by paroxetine in patients with major depression disorder: a 123I-ADAM SPECT study. Catafau AM; Perez V; Plaza P; Pascual JC; Bullich S; Suarez M; Penengo MM; Corripio I; Puigdemont D; Danus M; Perich J; Alvarez E Psychopharmacology (Berl); 2006 Dec; 189(2):145-53. PubMed ID: 17033844 [TBL] [Abstract][Full Text] [Related]
17. 123I-ADAM binding to serotonin transporters in patients with major depression and healthy controls: a preliminary study. Newberg AB; Amsterdam JD; Wintering N; Ploessl K; Swanson RL; Shults J; Alavi A J Nucl Med; 2005 Jun; 46(6):973-7. PubMed ID: 15937308 [TBL] [Abstract][Full Text] [Related]
18. Sex differences in diencephalon serotonin transporter availability in major depression. Staley JK; Sanacora G; Tamagnan G; Maciejewski PK; Malison RT; Berman RM; Vythilingam M; Kugaya A; Baldwin RM; Seibyl JP; Charney D; Innis RB Biol Psychiatry; 2006 Jan; 59(1):40-7. PubMed ID: 16139815 [TBL] [Abstract][Full Text] [Related]
19. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Meyer JH; Wilson AA; Sagrati S; Hussey D; Carella A; Potter WZ; Ginovart N; Spencer EP; Cheok A; Houle S Am J Psychiatry; 2004 May; 161(5):826-35. PubMed ID: 15121647 [TBL] [Abstract][Full Text] [Related]